ONC.TO : Summary for ONCOLYTICS BIO - Yahoo Finance

U.S. Markets closed

Oncolytics Biotech Inc. (ONC.TO)

Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
0.40+0.03 (+8.11%)
At close: 3:59PM EST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close0.37
Bid0.39 x
Ask0.40 x
Day's Range0.38 - 0.40
52 Week Range0.19 - 0.75
Avg. Volume176,675
Market Cap48.5M
PE Ratio (TTM)-3.54
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Accesswire27 days ago

    Research Reports Initiated on Healthcare Stocks Oncolytics Biotech, ProMetic Life Sciences, Resverlogix, and Helius Medical Technologies

    LONDON, UK / ACCESSWIRE / January 26, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected ...

  • PR Newswirelast month

    Oncolytics Biotech® Inc. Appoints Dr. Matt Coffey to the Role of President and CEO

    CALGARY, Jan. 19, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. ("Oncolytics" or the "Company") (ONC.TO) (ONCYF) today announced that Matt Coffey PhD, MBA, has been appointed to the role of President and Chief Executive Officer, effective immediately. Dr. Coffey had been serving as the Company's Interim President and Chief Executive Officer since early November 2016. "Dr. Coffey has transitioned seamlessly into his new role and, together with the expanded senior management team, has rapidly crafted plans to advance a range of clinical and operational initiatives," said Wayne Pisano, Chairman of Oncolytics' Board of Directors.

  • PR Newswire3 months ago

    Oncolytics Biotech® Inc. Announces Change to Board of Directors

    CALGARY, Dec. 6, 2016 /PRNewswire/ - Oncolytics Biotech® Inc. ("Oncolytics" or the "Company") (ONC.TO) (ONCYF) today announced that Dr. Brad Thompson has resigned from Oncolytics board of directors effective immediately. Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.  Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.